Faeth Therapeutics Corporate Update: Key Investor Highlights
Major Corporate Rebranding and Strategic Focus
- Sensei Biotherapeutics, Inc. has officially changed its name to Faeth Therapeutics, Inc. as of June 15, 2026. The company’s common stock will begin trading under the new ticker symbol “FTH” on the Nasdaq Capital Market starting June 16, 2026.
- The name change follows the February 2026 acquisition of Faeth Therapeutics and the approval by stockholders for the conversion of Series B preferred stock into common stock, effective June 15, 2026.
- A new corporate website has been launched at www.faeththerapeutics.com.
Financial Strengthening and Capital Raise
- The company secured approximately \$200 million in gross proceeds from a private placement that closed concurrently with the Faeth acquisition in February 2026. This capital infusion positions Faeth as a well-capitalized public company, backed by a syndicate of leading life sciences investors.
Pipeline and Clinical Catalysts
- Faeth’s lead program, PIKTOR, is an investigational, all-oral combination therapy targeting the PI3K/AKT/mTOR pathway, one of the most frequently altered pathways in cancer (dysregulated in up to 50% of all solid tumors).
-
Upcoming Catalysts:
- Topline Phase 2 data for PIKTOR in advanced endometrial cancer (Study FTH-PIK-201) is expected in the second half of 2026.
- Interim Phase 1b/2 data in HR+/HER2- advanced breast cancer (Study FTH-PIK-101) anticipated in 2027. The first patient in this study was dosed in April 2026.
- PIKTOR is designed to inhibit PI3K-alpha, mTORC1, and mTORC2 simultaneously, potentially overcoming a key resistance mechanism seen with single-node inhibitors in this pathway.
- The company believes this multi-node, all-oral approach may offer a best-in-class efficacy and tolerability profile, representing a differentiated strategy in targeting a high-prevalence oncogenic pathway.
Leadership and Governance Changes
- Anand Parikh, co-founder of Faeth, is now Chairman, President, and CEO.
- Brian Stephenson, Ph.D., CFA, previously Head of Operations and Finance at Faeth and former CFO of BridgeBio Pharma, is now Chief Financial Officer.
- Oliver Maddocks, Ph.D. serves as Chief Scientific Officer and Debbie Chirnomas, M.D., M.P.H. as Chief Medical Officer.
- The board now includes Stephen M. Hahn, M.D. (former FDA Commissioner), Saira Ramasastry (life sciences strategic advisor), Bob Holmen, and Phillip B. Donenberg.
- Dr. Hahn noted the scientific rigor and unmet need addressed by Faeth’s approach, emphasizing its potential to impact oncology drug development.
Key Considerations and Shareholder Impacts
- Name and Ticker Change: The switch to the FTH ticker and Faeth branding may affect the company’s visibility and investor perception.
- Conversion of Series B Preferred Stock: The automatic conversion of Series B preferred stock into common stock as of June 15, 2026, could impact share structure and liquidity.
- Significant Pipeline Catalysts: Positive or negative clinical data from ongoing PIKTOR studies could be highly price-sensitive, with the next major readout expected in the second half of 2026.
- Financial Position: With \$200 million in recent gross proceeds, Faeth is well-funded to advance its clinical programs, reducing near-term financing risk.
- Risks: Investors should note risks related to clinical trial outcomes, continued Nasdaq listing compliance, integration of Faeth operations, and the typical uncertainties inherent in drug development.
About Faeth Therapeutics
Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company developing multi-node inhibitors for critical oncogenic pathways in cancer. Its lead program, PIKTOR, combines serabelisib (PI3K-alpha inhibitor) and sapanisertib (mTORC1/mTORC2 inhibitor), with ongoing development in endometrial and breast cancers. The company was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., with scientific founders including Lewis Cantley, Ph.D. (discoverer of PI3K), Siddhartha Mukherjee, M.D., D.Phil., Karen Vousden, Ph.D., Scott Lowe, Ph.D., and Greg Hannon, Ph.D.
Investor and Media Contacts
- Matthew Biegler, SVP, Investor Relations – [email protected]
- Stephanie Ascher, Precision AQ – [email protected]
- Patrick Schmidt, Consort Partners – [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Forward-looking statements in this summary are subject to risks and uncertainties, including those outlined by Faeth Therapeutics in its SEC filings. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions.
